89 related articles for article (PubMed ID: 20037292)
21. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy of hematological malignancies using dendritic cells.
Van de Velde AL; Berneman ZN; Van Tendeloo VF
Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
[TBL] [Abstract][Full Text] [Related]
23. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cell vaccines in acute leukaemia.
Duncan C; Roddie H
Best Pract Res Clin Haematol; 2008 Sep; 21(3):521-41. PubMed ID: 18790453
[TBL] [Abstract][Full Text] [Related]
25. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma.
Caruso DA; Orme LM; Amor GM; Neale AM; Radcliff FJ; Downie P; Tang ML; Ashley DM
Cancer; 2005 Mar; 103(6):1280-91. PubMed ID: 15693021
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
27. Modification of dendritic cells with interferon-gamma-inducible protein-10 gene to enhance vaccine potency.
Kang TH; Bae HC; Kim SH; Seo SH; Son SW; Choi EY; Seong SY; Kim TW
J Gene Med; 2009 Oct; 11(10):889-98. PubMed ID: 19618483
[TBL] [Abstract][Full Text] [Related]
28. Different antitumor immunity roles of cytokine activated T lymphocytes from naive murine splenocytes and from dendritic cells-based vaccine primed splenocytes: implications for adoptive immunotherapy.
Zhang S; Wang Q; Li WF; Wang HY; Zhang HJ; Zhu JJ
Eksp Onkol; 2004 Mar; 26(1):55-62. PubMed ID: 15112581
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.
Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Sawai S; Inoue S; Abe H; Hanasawa K; Fujino S
Int J Mol Med; 2003 Oct; 12(4):493-502. PubMed ID: 12964025
[TBL] [Abstract][Full Text] [Related]
30. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma.
Higashi M; Yonezawa S; Ho JJ; Tanaka S; Irimura T; Kim YS; Sato E
Hepatology; 1999 Dec; 30(6):1347-55. PubMed ID: 10573510
[TBL] [Abstract][Full Text] [Related]
31. Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients.
Zeng ZC; Tang ZY; Fan J; Zhou J; Qin LX; Ye SL; Sun HC; Wang BL; Li D; Wang JH; Zeng MS; Guo W; Tan YS
Cancer J; 2006; 12(2):113-22. PubMed ID: 16630402
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy of the combination therapy in early stage of recurrent cholangio celluler carcinoma (CCC)].
Fujiwara S; Hasuike Y; Fukuchi N; Hayashi N; Kida H; Tsujie M; Yoshida T; Ebisui C; Sakita I; Fujimoto T
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1849-51. PubMed ID: 16315960
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic properties of DNA-based fibroblast and dendritic cell vaccines in mice with squamous carcinoma.
O-Sullivan I; Kim TS; Chopra A; Cohen EP
Anticancer Res; 2006; 26(2A):873-84. PubMed ID: 16619482
[TBL] [Abstract][Full Text] [Related]
34. Clinical impact of the surgical margin status in hepatectomy for solitary mass-forming type intrahepatic cholangiocarcinoma without lymph node metastases.
Shimada K; Sano T; Sakamoto Y; Esaki M; Kosuge T; Ojima H
J Surg Oncol; 2007 Aug; 96(2):160-5. PubMed ID: 17443744
[TBL] [Abstract][Full Text] [Related]
35. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide.
Oh ST; Kim CH; Park MY; Won EH; Sohn HJ; Cho HI; Kang WK; Hong YK; Kim TG
Vaccine; 2006 Apr; 24(15):2860-8. PubMed ID: 16443309
[TBL] [Abstract][Full Text] [Related]
36. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells.
Hao S; Bi X; Xu S; Wei Y; Wu X; Guo X; Carlsen S; Xiang J
Exp Oncol; 2004 Dec; 26(4):300-6. PubMed ID: 15627063
[TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
38. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma.
Cao DY; Yang JY; Yue SQ; Tao KS; Song ZS; Wang DS; Yang YL; Dou KF
Cell Immunol; 2009; 259(1):13-20. PubMed ID: 19545862
[TBL] [Abstract][Full Text] [Related]
39. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
40. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells.
Savai R; Schermuly RT; Pullamsetti SS; Schneider M; Greschus S; Ghofrani HA; Traupe H; Grimminger F; Banat GA
Cancer Res; 2007 Jun; 67(11):5443-53. PubMed ID: 17545626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
